Stryker (SYK) Expected to Announce Quarterly Earnings on Thursday

Stryker (NYSE:SYK) will likely be posting its Q4 2025 results after the market closes on Thursday, January 29th. Analysts expect Stryker to post earnings of $4.39 per share and revenue of $7.1205 billion for the quarter. Individuals may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Thursday, January 29, 2026 at 4:30 PM ET.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Friday, October 31st. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. Stryker had a net margin of 12.07% and a return on equity of 24.07%. The business had revenue of $6.06 billion during the quarter, compared to the consensus estimate of $6.04 billion. During the same period in the prior year, the firm posted $2.87 EPS. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. On average, analysts expect Stryker to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Stryker Price Performance

Stryker stock opened at $354.66 on Wednesday. Stryker has a 52 week low of $329.16 and a 52 week high of $406.19. The company’s 50 day moving average price is $359.63 and its two-hundred day moving average price is $372.17. The stock has a market cap of $135.63 billion, a P/E ratio of 46.60, a P/E/G ratio of 2.29 and a beta of 0.89. The company has a quick ratio of 1.13, a current ratio of 1.85 and a debt-to-equity ratio of 0.68.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 30th. Investors of record on Wednesday, December 31st will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 1.0%. This is an increase from Stryker’s previous quarterly dividend of $0.84. The ex-dividend date is Wednesday, December 31st. Stryker’s dividend payout ratio is 46.25%.

Insiders Place Their Bets

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the firm’s stock in a transaction dated Friday, November 14th. The shares were sold at an average price of $365.49, for a total value of $713,801.97. Following the completion of the sale, the chief accounting officer directly owned 2,833 shares of the company’s stock, valued at approximately $1,035,433.17. This trade represents a 40.81% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of Stryker stock in a transaction dated Thursday, November 6th. The shares were sold at an average price of $353.28, for a total transaction of $97,566,397.44. Following the sale, the director directly owned 2,702,108 shares in the company, valued at $954,600,714.24. The trade was a 9.27% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 522,118 shares of company stock worth $185,381,932. 5.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. United Financial Planning Group LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $27,000. Strive Asset Management LLC purchased a new position in Stryker during the third quarter valued at $30,000. Wiser Advisor Group LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $61,000. Quarry LP purchased a new stake in shares of Stryker in the 3rd quarter worth about $63,000. Finally, Binnacle Investments Inc increased its stake in shares of Stryker by 26.1% in the 2nd quarter. Binnacle Investments Inc now owns 179 shares of the medical technology company’s stock worth $71,000 after acquiring an additional 37 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Sunday, December 21st. Weiss Ratings restated a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. BTIG Research restated a “buy” rating and set a $410.00 price objective on shares of Stryker in a report on Friday, November 14th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $435.00 target price on shares of Stryker in a research note on Friday, November 14th. Finally, Raymond James Financial upgraded shares of Stryker from a “market perform” rating to an “outperform” rating and set a $418.00 price target for the company in a research note on Tuesday, January 6th. Fifteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $427.95.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.